The global mRNA therapeutics market size is expected to reach USD 37.76 billion by 2030. It is expected to expand at a CAGR of 1.7% from 2022 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs.

The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

mRNA therapeutics Market Size & Market Analysis

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favourable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
For instance, in March 2022, The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.
As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

mRNA therapeutics Market Size & Market Analysis

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer or metastasis cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.
Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

List of main Players in the mRNA Therapeutics Market Size & Market Analysis :

Moderna, Inc.
BioNTech SE
CureVac N.V.
Arcturus Therapeutics
Translate Bio, Inc.
GSK plc.
Argos Therapeutics Inc.
Sangamo Therapeutics, Inc.
Pfizer Inc.
AstraZeneca plc.
CRISPR Therapeutics AG

Source : https://www.researchandmarkets.com/reports/5644939/global-mrna-therapeutics-market-size-share-and#:~:text=The%20global%20mRNA%20therapeutics%20market%20size%20is%20expected,infectious%20diseases%20like%20diabetes%2C%20HIV%2C%20cancer%2C%20and%20CVDs.

The global Metastasis Cancer Treatment Market size in terms of revenue was worth of $63.18 Billion in 2020 and is expected to reach $161.67 Billion in 2027, growing at CAGR of 12.3% from 2021 to 2027.

Metastasis cancer represents the advanced form of cancer, which occurs when the cancer cells start spreading from the site of origin to different parts of the body. Treatment for Metastasis cancer aims to slow the expansion or spread of the cancer. Treatment depends on the sort of cancer, where it started, the dimension and location of the metastasis and other factors. The treatment for Metastasis cancer is often different from the ones used for a normal tumor. Treatment of Metastasis cancer is often not curable and is mainly focused on providing relaxing care. Several manufactures are investing in oncology market and are making vigorous efforts for the supply of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to capture their condition, which is turn, is increasing the adoption rate of the Metastasis cancer treatment drugs.

Metastasis occurs when cancer progresses to different parts of the body from where it originated and it is the culmination of neoplastic progression. Cancer metastasis is a major challenge in cancer treatment as it is difficult to diagnose and treat. Metastasis accounts for 90% of cancer associated mortality and only a small number of patients with metastatic cancer can be treated with conventional strategies such as chemotherapy, radiotherapy and surgical removal.

Metastasis Cancer Treatment Market size & Market Analysis

Increasing focus on development of new strategies to prevent metastasis, rapid adoption of stem cells and oncolytic viruses to treat metastatic cancer, and growing caseload of cancer across the globe are some key factors expected to drive market revenue growth over the forecast period. In addition, increasing research and development activities to understand molecular mechanisms of metastasis and rising number of clinical trials to develop personalized treatments that can specifically target metastases are some other key factors expected to contribute revenue growth of the market going ahead.

The major drivers for the global Metastasis cancer treatment market growth are rising prevalence of cancer and high medical needs of patients who have Metastasis cancer. Rising prevalence of Metastasis cancer is one of the major factors expected to drive the growth of the global Metastasis cancer treatment market. It is estimated that metastasis is responsible for about 90% of cancer deaths. This estimate has changed little in more than 50 years, according to National Center for Biotechnology Information. The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development. Breast cancer is the second most common cause of death from cancer in 6% women. It is estimated that 42,690 people will die from breast cancer, according to American Society of Clinical Oncology. Metastasis breast cancer will cause the vast majority of those deaths. However, high cost of Metastasis cancer treatment may hamper the growth of this market. In spite of that, increasing number of pharmaceutical, biotechnology and diagnostic companies are focusing on research and development of innovative oncology medicines to provide advanced treatment which may create more opportunities for the further growth of the market.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis is the major reason for treatment failure in cancer patients and accounts for majority of cancer-related deaths. Metastasis also causes treatment failure even in tumors that are sensitive to chemotherapy or radiotherapy. Metastatic tumors are difficult to treat with conventional therapy due to their anatomically diffuse localization and resistance to cytotoxic agents. Rapid technological advancements in imaging and cancer cell identification have significantly improved understanding of cancer metastasis. Treatment of metastatic cancer primarily aims to slow the growth or spread of cancer and typically requires systemic therapy or oral or intravenous medications to reach cancer cells throughout the body.

Other treatment approaches include immunotherapy, radiation therapy, surgical intervention, or a combination of these treatments. In addition, clinical trials offer access top novel treatment approaches that can prove to be more appropriate and effective as compared to standard of care options. Various therapeutic options are available to ease side effects and enhance quality of life of patients even after metastatic cancer has stopped responding to treatments. Development of new strategies to manage and treat metastatic cancer and advancements in stem cell therapy are some factors expected to drive market revenue growth over the forecast period.

However, difficulties associated with the treatment of metastatic cancer, high costs of cancer treatment, and resistance of metastatic cells to conventional treatment approaches and cytotoxic agents are some key factors expected to restrain market growth to a certain extent over the forecast period. In addition, lack of knowledge regarding metastatic processes, recurrence of cancer, and systemic side effects of treatment are some other factors expected to hamper market growth to a certain extent over the forecast period.  

North America is the highest revenue generating market for Metastasis cancer treatment solutions. The rate of diagnosis is high in this region due to advances healthcare infrastructure and awareness among the people. According to American cancer society; in 2016; there were approximately 3.5 million women living with an antiquity of breast cancer in the United States. More than 16.9 million Americans with a history of cancer were alive on January 1st, 2019, and this number is projected to grow to more than 22.1 million by January 1st, 2030, according to Carevive Systems, Inc. Europe is second largest region for this market due to rising Advancements in immune-oncology and precision medicine. Immense scientific innovation in the field of oncology has resulted in higher regulatory approval rates of cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy, among others in this region. In 2017, more than 3,500 radiation therapy machines were used by hospitals and providers of ambulatory health care in the European Union (EU). The performance of breast-protection surgery has increased, and the use of neoadjuvant therapy to downstage locally advanced breast cancer has become more common in the Asia–Pacific region.

Metastasis Cancer Treatment – Main Players :

List of main players in the Global Metastasis Cancer Treatment Market size & Market Analysis :

• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• BRISTOL-MYERS SQUIBB COMPANY
• Eli-Lilly and Company
• Hoffmann-La Roche AG
• JOHNSON & JOHNSON
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• SANOFI

Source Metastasis Cancer Treatment Market size & Market Analysis : https://brandessenceresearch.com/healthcare/metastasis-cancer-treatment-market

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, 2022 – 2031. The market is estimated to garner a revenue of near to USD 11980 Million by the end of 2031, up from a revenue of more than USD 4350 Million in the year 2021.

The liposomal doxorubicin segment, by the end of 2031, is projected to garner the largest revenue of about USD 3220 Million. Additionally, in the year 2021, the segment generated a revenue of near to USD 1140 Million. The market in North America, by the end of 2031, is projected to garner the largest revenue of close to USD 4430 Million. Additionally, in the year 2021, the market in the region generated a revenue of around USD 1690 Million.

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, 2022 – 2031. Factors such as the surge in concern for the rising prevalence of cancer around the globe, along with the increasing adoption of advanced drug delivery systems for the treatment of the disease are anticipated to drive the growth of the market in the coming years.

Additionally, factors such as the surge in use of liposomes as drug delivery systems, and the numerous benefits associated with the use of liposomes for drug delivery in cancer treatment are also projected to boost the market growth during the forecast period. The market is estimated to garner a revenue of near to USD 11980 Million by the end of 2031, up from a revenue of more than USD 4350 Million in the year 2021.

Liposomal Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is segmented by numerous segments, which include segmentation by product, technology, application, and by region. By product, the market is segmented by product into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. The liposomal doxorubicin segment, by the end of 2031, is projected to garner the largest revenue of about USD 3220 Million. Additionally, in the year 2021, the segment generated a revenue of near to USD 1140 Million.

On the basis of regional analysis, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America, by the end of 2031, is projected to garner the largest revenue of close to USD 4430 Million. Additionally, in the year 2021, the market in the region generated a revenue of around USD 1690 Million.

Major players in the Liposome Drug Delivery Market Size & Market Analysis :

• Spectrum Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Celsion Corporation
• Ipsen Pharma
• Pacira Pharmaceuticals Inc.
• Novartis AG
• CordenPharma International
• FUJIFILM Toyama Chemical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson Services Inc.
• Astellas Pharma Inc.
• Elan Pharmaceuticals (Perrigo Company plc)
• Merrimack Pharmaceuticals Inc.
• Janssen Pharmaceuticals Inc.

Liposome Drug Delivery Market Size & Market Analysis

Source : https://www.researchandmarkets.com/reports/5624580/global-liposome-drug-delivery-market-analysis

The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The market is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%.

North America is the largest region in the bladder cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The American Cancer Society’s estimates for bladder cancer in the United States for 2021 are about 83,730 new cases of bladder cancer. In addition, the rising geriatric population, unhygienic sedentary lifestyle, and smoking habits are increasing the prevalence of most cancer cases.

When the cells that make up the urinary bladder begin to proliferate out of control, bladder cancer develops. More cancer cells can form a tumor and spread to other places of the body as time goes on. The bladder wall is made up of multiple layers. Each layer is made up of many cell types. The urothelium or transitional epithelium, which lines the inside of the bladder, is where most bladder malignancies begin. Cancer progresses to a higher stage, gets more advanced, and is more difficult to cure when it spreads into or through the other layers of the bladder wall. Cancer may spread outside the bladder and into neighboring structures over time. It could spread to nearby lymph nodes or other organs.

Bladder Cancer Drugs Market size & Market analysis

The most frequent type of bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma (TCC). Urothelial carcinoma is virtually always been the cause of bladder cancer. Squamous cell carcinomas account for about 1% to 2% of bladder malignancies in the United States. The cells, when viewed under a microscope, resemble the flat cells present on the skin’s surface. Squamous cell carcinomas of the bladder are almost always invasive. Adenocarcinomas make up roughly 1% of all bladder cancers. These cancer cells have a lot in common with colon cancer gland-forming cells. Almost of bladder adenocarcinomas are invasive. Small-cell carcinomas account for less than 1% of bladder cancers. They begin in neuroendocrine cells, which are nerve-like cells. These cancers grow quickly and require chemotherapy, similar to that used to treat small cell carcinoma of the lung. Sarcomas begin in the bladder’s muscle cells, but they are extremely rare. Soft Tissue Sarcoma and Rhabdomyosarcoma have more information. These less common kinds of bladder cancer (apart from sarcoma) are treated similarly to TCCs, especially in the early stages, but alternative drugs may be used if chemotherapy is required.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale.

This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells.

Bladder Cancer Drugs Market size & Market analysis

Source : https://www.researchandmarkets.com/reports/5559826/bladder-cancer-drugs-global-market-report-2022

The global COVID-19 diagnostics market size was valued at USD 97.4 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.7% from 2022 to 2030. The market is driven by the rising government initiatives targeted toward the implementation of mass testing.

Transitioning focus of new entrants toward at-home testing and integration of advanced software has been witnessed in the past few months. This is expected to increase patient convenience in regard to time-consuming laboratory-based testing. 

The considerable increase in patient population around the world, the enormous need for speedy diagnostics, and the lack of specific drug or vaccination are the primary factors driving the market for Covid-19 diagnostics. However, a lack of awareness among developing countries about the precautions that must be taken, as well as a scarcity of diagnostic kits and medical professionals with sufficient understanding about the use of diagnostic kits for new Covid-19, are expected to stymie market expansion. Leading diagnostic kit producers, on the other hand, can benefit from a number of profitable ventures by manufacturing rapid diagnostic kits. Moreover, several local players and small startups are producing diagnostic kits and assays to take advantage of huge prospects. For example, once the National Institute of Virology confirmed its test, Mylab, India gained permission from the Drug Controller of India for manufacturing the Covid-19 diagnostic kit.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

The demand for COVID-19 diagnostic products is set to propel further with the increasing number of coronavirus-infected patients, particularly post the ease of lockdown across the globe. According to World meter, the total number of cases witnessed a spike with 33,556,252 patients testing positive as of 28^th September 2020 to 55,961,380 patients on 17^th November 2020. Despite the gradual decline expected in the number of positive patients in 2021, integration of COVID-19 tests in routine diagnostic protocols is expected to maintain the growth of the market for Covid-19 diagnostics.

Moreover, these testing programs are set to pave way for the travel industry to gear up, creating a favorable environment for the entities operating in the market for Covid-19 diagnostics. The tourism and travel industries have been most affected during this pandemic outbreak, which has led to an upsurge in COVID-19 testing initiatives post August 2020, particularly in tourism-based countries and regions. This is also expected to propel the PoC testing market penetration as these tests are able to overcome the limitations associated with traditional testing.

Complex and pure reagents, such as probes, enzymes, and primers, are crucial in conducting tests in clinical laboratories. A number of factors like a sudden increase in demand, export bans, and stockpiling have led to the shortage of these reagents. Additionally, these reagents are manufactured by limited companies, therefore leading to a shortage of supply due to insufficient production capacity. The inadequate demand-to-supply ratio of reagents worldwide is anticipated to negatively impact the overall diagnosis rate and hinder the growth of the market for Covid-19 diagnostics.

The market for Covid-19 diagnostics is divided into two segments based on technology: PCR and immunoassay. Because of the rising need for coronavirus patient diagnosis, the PCR segment is likely to rise rapidly in the near future. Furthermore, PCR is regarded as the gold standard for detecting COVID-19 infections. The immunoassay segment is expected to increase at the fastest rate throughout the forecast period, due to a rise in the need for quick serological testing for disease diagnosis. A plethora of serological kits is being developed to confirm Sars Cov 2 infections.

The services segment is estimated to dominate the market for Covid-19 diagnostics and accounted for revenue share of 47.8% in 2021. Service providers are boosting their testing capabilities by expanding technological footprints in existing labs and diagnostic centers as well as by launching new, high-capacity laboratories, which has contributed to the segment growth. Collaborations between governments, test developers, public health organizations, and private laboratories accelerate the expansion of testing capacities. 

The reagents and kits segment is expected to register a CAGR of (7.2%) from 2020 to 2030. The reduction in the number of active COVID-19 cases is responsible for the declining market growth of this segment. In response to the pandemic, companies are implementing various strategic initiatives, such as new product development and collaborations.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

Source : https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market

The global COVID-19 Therapeutics market size was valued at US$ 10.2 Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record a promising CAGR of 10.7% from 2021 to 2030.

COVID-19 is a contagious disease triggered by the most recently discovered coronavirus, which has affected millions of individuals worldwide. The coronavirus can be treated with various drugs, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. In August 2021, The World Health Organization (WHO) released a report that represents Artesunate, imatinib, and infliximab are three new potential medications being investigated in the latest phase of the global Solidarity clinical trials to find effective COVID-19 therapies. Additional medicines approved for emergency use include Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology’s Xevudy (sotrovimab); Roche’s Actemra; Celltrion’s Regkirona; and convalescent plasma. The growth of the COVID-19 Therapeutics Market is primarily attributed the increased prevalence of COVID-19 across the globe. In the first week of January 2022, Covid-19 cases have now been recorded in over 300 million people worldwide. The United States had over 50 million confirmed cases and over 800,000 deaths, making it the Country with the highest death toll. Pharmaceutical companies are investing heavily in product research due to the rising pandemic effect, and they are focusing on the production of enhanced therapeutics that can cure the covid-19. The market is further supported by rising awareness about coronavirus and collective efforts by the pharmaceutical companies and government in the development of covid-19 therapeutic drugs.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The prominent players in the COVID-19 Therapeutics industry include Atea Pharmaceuticals, Inc., Fulcrum Therapeutics, CytoDyn, Eli Lilly and Company, Celltrion, Shanghai Junshi Biosciences Co., Ltd., NRX Pharmaceuticals, Veru Inc., Catalent, Inc., Humanigen, Inc., Molecular Partners AG, Cipla Limited, Merck, Regeneron Pharmaceuticals, Inc., Novartis International AG, Vir Biotechnology, Brii Biosciences Limited, Revive Therapeutics Ltd., GlaxoSmithKline plc, APEIRON Biologics AG, Janssen Pharmaceuticals, Bristol Myers Squibb, Trevena Inc, Constant Therapeutics LLC, Ono Pharmaceutical Co., Ltd., Amarin Corporation plc, NeuroBo Pharmaceuticals, Inc., FUJIFILM Toyama Chemical Co., Ltd., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, BioAegis Therapeutics, Pfizer, Takeda, Roivant Sciences, Celltex Therapeutics, Blade Therapeutics, A.I. Therapeutics, Inc., Marinomed Biotech AG, Synairgen, Romark Laboratories, SAb Biotherapeutics, Kiniksa Pharmaceuticals, UNION therapeutics A/S, etc.

COVID-19 Therapeutics Market Regional Analysis

In 2021, North America is expected to have the largest share of R&D in the global covid-19 therapeutics market, owing to increased government spending on drug development, growing government initiatives for covid-19 vaccine R&D, an increasing number of market players, and the implementation of favorable government initiatives in the U.S. and Canada. However, due to increased government initiatives to increase medication production and the number of research and development activities, the Asia Pacific area is predicted to grow rapidly in the target market. In June 2021, India’s pharma regulator approved the emergency use of Eli Lilly and Company India’s antibody medication combination, which is used to treat mild to moderate COVID-19 patients. The monoclonal antibody medications bamlanivimab 700 mg, and etesevimab 1400 mg have been approved by the company. Both of these medicines are utilized to treat COVID-19 patients who have mild to moderate symptoms.

The Global COVID-19 therapeutics Market Segments : Antiviral , Monoclonal Antibodies, Glucocorticoid, Anticoagulant, Nitric oxide and Other Drug Class.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

Source : https://www.bloomberg.com/press-releases/2022-01-18/global-covid-19-therapeutics-market-worth-14-6-billion-by-2022-exclusive-report-by-insightace-analytic and https://www.insightaceanalytic.com/report/global-covid-19-therapeutics-market/1184

The market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%. The global bi-specific mabs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

Bispecific mAbs – Bispecific Antibodies Market Size & Market Analysis

The main types of bi-specific are catumaxomab (removab), blinatumomab, duligotumab, SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types include in vivo, in vitro that are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, others.

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective over monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression.

According to the World Health Organization, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively.

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents.

For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographis paniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes.

Companies in the bispecific mAbs antibodies market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company.

Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are

• Johnson & Johnson
• Novartis AG
• Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Bayer AG
• Thermo Fisher Scientific, inc.
• Bistro-Myers Squibb. Mylan N.V.
• Daiichi Sankyo Company, Ltd.
• Abbott
• AstraZeneca
• Eli Lilly
• Merck & Co. inc.
• Amgen inc.
• Pfizer inc.
• GlaxoSmithKline plc.
• Roche
• Sanofi
• Genentech
• Immunomedics
• Chugai Pharmaceutical
• EMD Serono
• Emergent BioSolutions
• Jounce Therapeutics
• MarcoGenics
• Merus
• Neovii Biotech
• NovImmune SA
• OncoMed Pharmaceuticals
• Pieris
• Regeneron Pharmaceuticals

Bispecific mAbs – Bispecific Antibodies Market Size & Market Analysis

Source : https://www.researchandmarkets.com/reports/5553759/bi-specific-mabs-global-market-report-2022

The autoimmune disease diagnostics market was valued at USD 4,253.30 million in 2021 and is projected to reach USD 6,298.98 million by 2027 registering a CAGR of nearly 6.8% during the forecast period.

The first wave of COVID-19 pandemic has disrupted almost all areas of the health care services to some extent throughout the world. The negative impact of COVID-19 on patients with autoimmune diseases has also been recognized. According to an article titled “The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned” published in October 2021, a decrease in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. All autoantibody tests saw a 13% decrease, ranging from 1.4% in Switzerland to 25.5% in the United States (Greece). The decrease was most pronounced in all countries during the first wave of the pandemic (March-May 2020), with an overall decrease of 45.2% in those three months. The decrease was less pronounced(6.8%) in the second wave of the pandemic (October-December 2020).

The rising autoimmune diseases is the major factor behind the market growth. According to scientists at the National Institutes of Health and their collaborators, autoimmunity, a condition in which the body’s immune system reacts with components of its own cells, appears to be increasing in the United States. Also, as per the article published in January 2022, Autoimmune diseases are becoming more prevalent around the world. The global spread of Western diets is linked to higher levels of autoimmune disease. As per the same source, Tens of millions of people develop autoimmune diseases in the US alone, and the number of cases has been increasing in recent decades. Thus, the increasing autoimmune diseases is driving the market growth.

Autoimmune Diseases Diagnostics Market Size & Market Analysis

The rising awareness about autoimmune diseases through programs of research, education, support, and advocacy is a key factor boosting the usage rates of autoimmune disease diagnostics, globally. Government organizations and NGOs aims to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, and technological advancements, are driving the autoimmune disease diagnostics market. However, the slow turnaround time of the diagnosis and high frequency of false results are hindering the growth of the autoimmune disease diagnostics market.

Autoimmunity involves the loss of normal immune homeostasis, as the organism produces an abnormal response to its own tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation. Diagnosis of potential autoimmune diseases is very difficult, because not one laboratory test alone can produce diagnosis results for the disease. The diagnosis can be useful in the management of patients suffering from autoimmune diseases and help in providing a prognosis or indicating the severity of organ involvement or damage. The Autoimmune Disease Diagnostics Market is Segmented by Disease Type ( Systemic Autoimmune Disease​ ( Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, Other Systemic Autoimmune Diseases) and Localized Autoimmune Disease (Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid, and Other Localized Autoimmune Diseases​), Diagnosis Type (Antinuclear Antibody Tests​, Autoantibody Tests​, Complete Blood Count (CBC)​, C-reactive Protein (CRP)​, Urinalysis​, Others tests), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). 

Autoimmune Diseases Diagnostics Market Size & Market Analysis

Source : https://www.mordorintelligence.com/industry-reports/global-autoimmune-disease-diagnostics-market

The global transplantation market is expected to grow at a CAGR of 9.5% during forecast period 2020 to 2027 and projected to hit around USD 27.07 billion by 2027. The global transplantation market was valued at USD 13.10 billion in 2019.

Rising demand for the organ transplantation to treat organ failure and novel tissue transplantation products is the prime factor that drives the market growth.

Organ failure occurs because of various factors that include loss of blood, serious trauma, drug abuse, poisoning, sepsis, leukemia, and other acute diseases. Demand for organ and tissue transplantation mainly heart, kidney, lungs, and liver is very high. Alcohol consumption, unhealthy dietary habits, drug abuse, and lack of exercise are some of the major causes of organ failure. This expected to trigger the demand for transplantation products in the coming years. Additionally, increasing number of acute diseases has also resulted in the rising cases of organ failure.

Transplantation Market Size & Market Analysis

However, customary and religious belief along with lack of awareness related to organ donation prevents large number of people from donating organs. Thus, shortage of organs for the treatment of organ transplantation is likely to hinder the market growth. There is a massive gap between the supply and demand of organ for the treatment of organ failure. As per the U.S. Department of Health & Human Services report in 2019, total number of patients for kidney transplantation was 43,201, yet only 23,401 procedures for kidney transplantation were performed.

Product Type Insights

Tissue product segment was the highest revenue contributor in the global transplantation market in 2019, accounting for a market value share of nearly 58%. Significant rise in the transplantation procedures such as heart valves, cochlear, orthopedic soft tissues, and bone marrow prominently drives the growth of the segment. Further, advancement and development of new transplantation products is the other most important factor that propels the market growth. For instance, in September 2015, Arthrex Inc. introduced ArthroFlexAcellular Dermal Matrix, an orthobiologic product that is generally used capsular reconstruction.

On the other hand, immunosuppressive drugs segment projected to exhibit the fastest growth during the forecast period. This is mainly attributed to the increasing use of these drugs to prevent the post-transplant organ or tissue rejection. Rising number of chronic diseases has significantly boosted the organ transplantation market, which in turn expected to fuel the growth for immunosuppressive drugs over the analysis period.

Application Insights

Tissue transplantation application segment emerged as the global leader in the global transplantation market, with a revenue share of around 60% in the year 2019 and projected to expand at the fastest rate during the forecast period. This is attributed to the fact that replacement of cornea, skin, heart valves, bones, nerves, tendons, and veinsare the most common procedures performed globally. Furthermore, the increasing cases of burn and accidents expected to fuel the demand for tissue products in the coming years.

Besides this, organ transplantation analyzed to exhibit significant growth over the forecast period. Increasing number of organ transplant procedures along with recurring sales of immunosuppressant drugs is likely to boost the segment growth. For instance, in 2017, there were nearly 90,306 kidney transplant procedures performed worldwide.

End-use Insights

Hospital segment dominated the global transplantation market with value share of approximately 49% in the year 2019 and analyzed to retain its dominance over the forecast period. This is mainly due to increasing number of tissue and organ transplantation at hospitals as they are the primary health treatment centers. In addition, significant advancement along with rising investment for developing hospital Infrastructure equipped with advanced facilities attracts major audience.

On the contrary, transplant centers registered the highest growth rate during the forecast period. Increasing number of transplantations has triggered the need for large number of health centers to cater the patient requirement. Additionally, the rising government initiatives to encourage the public for organ donation again flourish the market growth.

Regional Insights

North America encountered as the most prominent region leading the global transplantation market with significant revenue share of nearly 40% in 2019 and projected to maintain its dominance throughout the analysis period. Well-developed health treatment facilities along with the presence of several major medical devices as well as biotechnologies manufacturing companies such as Zimmer Biomet, Arthrex, Inc., Novartis AG, Medtronic, and Stryker supports the market growth.

However, the Asia Pacific registered the fastest growth over the analysis period due to increasing research activities on stem cells for developing organs and in vitro tissue. Furthermore, developing healthcare infrastructure in various Asian countries such as Thailand, India, Indonesia, and Philippines analyzed to propel the market growth in the region.

Key Companies & Market Share Insights

The global transplantation market is highly fragmented with the presence of several small, medium, and large scale vendors. Major market players focus mainly on mergers & acquisitions, new product launch, and regional expansions to gain significant momentum in terms of revenue share in the industry. Mergers and acquisitions help vendors to expand their geographical reach and existing product portfolio.

Some of the prominent players in the transplantation market include:

• Arthrex, Inc.
• Abbvie, Inc.
• Teva Pharmaceuticals
• Medtronic PLC
• Zimmer Biomet
• Strykers
• Novartis AG
• BiolifeSolutions, Inc.
• 21st Century Medicine
• Veloxis Pharmaceutical

Transplantation Market Size & Market Analysis

Source : https://www.precedenceresearch.com/transplantation-market

The global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$579.8 Million in the year 2020, is projected to reach a revised size of US$766.7 Million by 2026, growing at a CAGR of 4.8% over the analysis period.

Serology Tests, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$561.3 Million by the end of the analysis period.

After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Monitoring Ra Treatment Efficiency Tests segment is readjusted to a revised 4% CAGR for the next 7-year period. This segment currently accounts for a 31.6% share of the global Rheumatoid Arthritis Diagnosis Tests market.

Though the disease can attack at any age its prevalence generally begins in people between 30 to 60 years of age. Females are more two to three times more prone to RA than men. The US had the lowest rate of RA prevalence in the recent past in comparison to the other eight major markets like Australia, the US, Japan, France Italy, Germany, Spain and the UK.

The US had an RA prevalence rate of 67% in comparison with the standard 73% rate in the other eight markets. The UK demonstrated the highest prevalence of RA at 84%. Alterations in the population of the U.S are expected to bring an unprecedented increase in the growth of incidence cases of RA in the U.S. till 2027.

Rheumatoid Arthritis Diagnostics Tests Market Size & Market Analysis

Physicians in the U.S. are expected to focus heavily on diagnostic processes for RA. Rheumatoid arthritis is better managed when detected early as the inflammation reduction process can be begun early. The clinical demonstration of RA is swelling and redness of joints, pain, swelling and stiffness. Diagnosing the disease involves a physical examination, an array of imaging tests, blood tests and medical history analysis of patients and patient`s families.

The diagnosis of RA can be influenced by the challenge of separating the disease from other autoimmune disorders showing similar symptoms. A combination of diagnostic processes including a thorough symptomatic evaluation of the patient, X-ray analysis, blood tests and scans and physical examinations are recommended for the optimal management of this disease.

The U.S. Market is Estimated at $124.3 Million in 2021, While China is Forecast to Reach $113.5 Million by 2026

The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$124.3 Million in the year 2021. The country currently accounts for a 20.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.5 Million in the year 2026 trailing a CAGR of 6.1% through 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$120.4 Million by the close of the analysis period.

Global demographic trends spell opportunities for the rheumatoid arthritis (RA) diagnostic tests market. It is acknowledged that prevalence of RA increases with age, and therefore rising aging population widens the demand for diagnosis tests as well as treatments for RA. Over the course of the next two decades, the proportion of 65+ individuals in the total population is expected to double in countries such as the US, UK and Australia.

With advancing age, the incidence of various health ailments increases, necessitating the need for laboratory tests for diagnosing the specific diseases such as RA. Impact of autoimmune diseases such as RA on quality of life and associated high cost of treatments are prompting governments and healthcare providers to encourage preventive care, especially with focus on aging population.

The growing aging population is therefore offering continuous opportunities for the autoimmune disease diagnostics market, as with advancing age the incidence of various autoimmune conditions such as RA increases, which results in rise in testing volumes translating to higher demand for testing techniques for RA.

As RA is mostly common among the old people, and the geriatric population has been increasing recently, the opportunities in the global rheumatoid arthritis diagnosis test market are expected to be on the rise in the future.

Rheumatoid Arthritis Diagnostics Tests Market Size & Market Analysis

Source : https://www.businesswire.com/news/home/20211008005236/en/Rheumatoid-Arthritis-Diagnosis-Tests-Market—Global-Trajectory-Analytics-to-2026—ResearchAndMarkets.com